At every stage of the product lifecycle, pharmaceutical companies are subject to strict regulations and must maintain compliance with local governing bodies.
In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products.